Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104035 | 0.83 | SMPD1 (0.36) | TDP1 | |
| SCHEMBL13104241 | 0.81 | FFAR1 (0.42) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL13104546 | 0.80 | CYP2C9 (0.33) | — | |
| SCHEMBL13104033 | 0.80 | S1PR2 (0.33) | — | |
| SCHEMBL2710896 | 0.79 | HMGCR (0.42) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL13104248 | 0.79 | SMPD1 (0.33) | — | |
| SCHEMBL13104036 | 0.77 | SMPD1 (0.33) | CYP2C19 | |
| SCHEMBL13104590 | 0.77 | SMPD1 (0.33) | — | |
| SCHEMBL17232567 | 0.76 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL28626698 | 0.76 | FFAR1 (0.48) | KDM4EFFAR1CPT2TDP1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | KDM4E 1880/4885FFAR1 43/4885CPT2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.